Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Metabolomics of muscle in insulin sensitive and resistant obese indivduals. (Study ST000841)

C18 NEGATIVE ION MODE/Triple TOF (Analysis AN001351)

Metabolite	Structure	F1	F2	F3	F4
PE 33:2; [M-H]-@6.08	ME222888	0.69	0.56	1.13	3.58
PS 40:8; [M-H]-@4.98	ME222948	0.59	1.08	0.88	3.08
lysoPE 20:3; [M-H]-@1.61	ME222950	1.53	0.47	1.05	0.50
CerP 42:2; [M-H]-@7.66	ME222837	0.87	1.10	0.83	1.97
PC 40:2; [M-Ac-H]-@7.83	ME222880	0.93	0.79	1.00	2.18
CL 70:1; [M-2H](2-)@6.02	ME222817	0.87	0.93	0.97	2.02
PC 42:10; [M-Ac-H]-@5.68	ME222882	0.89	0.94	0.92	2.08
PE 36:5; [M-H]-@5.95	ME222898	0.93	0.97	0.84	2.16
PG 36:3; [M-H]-@5.30	ME222922	0.83	0.97	0.92	2.22
PE 30:0; [M-H]-@6.08	ME222885	0.98	0.57	1.12	2.24
PC 37:6; [M-Ac-H]-@5.79	ME222874	1.00	0.83	0.85	2.36
PG 33:0; [M-H]-@6.09	ME222916	1.02	0.71	0.90	2.49
PC 30:2; [M-Ac-H]-@4.87	ME222861	0.97	0.75	0.95	2.41
PI 36:1; [M-H]-@6.32	ME222927	0.98	0.72	0.97	2.35
PC 38:7; [M-Ac-H]-@5.51	ME222876	0.79	0.78	1.22	1.79
CL 74:8; [M-2H](2-)@9.20	ME222828	0.84	0.96	1.06	1.63
PC 32:1; [M-Ac-H]-@6.05	ME222863	0.84	0.95	1.06	1.67
CL 70:7; [M-2H](2-)@8.87	ME222820	0.94	0.86	1.01	1.76
PE 37:5; [M-H]-@5.71	ME222900	0.94	0.91	0.99	1.64
plasmenyl-PE 42:5; [M-H]-@7.86	ME222969	0.92	0.90	1.02	1.69
CL 70:5; [M-2H](2-)@5.92	ME222818	0.82	0.99	1.00	1.87
PG 36:4; [M-H]-@4.95	ME222923	0.72	1.13	0.98	1.88
PE 34:4; [M-H]-@5.70	ME222891	0.69	1.06	1.07	1.79
PC 35:1; [M-Ac-H]-@6.95	ME222867	0.75	1.03	1.05	1.75
PE 34:3; [M-H]-@5.98	ME222890	0.73	1.06	1.04	1.77
PE 32:1; [M-H]-@6.21	ME222887	0.94	0.74	1.08	1.96
plasmenyl-PE 30:0; [M-H]-@6.45	ME222954	0.95	0.72	1.09	1.95
CL 66:1; [M-2H](2-)@6.22	ME222816	1.01	0.57	1.17	1.90
PE 44:4; [M-H]-@8.52	ME222914	1.16	0.52	1.07	1.85
FFA(24:1)	ME222850	1.11	0.86	0.82	1.87
PA 38:6; [M-H]-@6.09	ME222858	1.11	0.86	0.85	1.77
PC 28:0; [M-Ac-H]-@5.21	ME222860	1.07	0.79	0.92	1.91
PS 40:4; [M-H]-@6.43	ME222944	1.09	0.77	0.94	1.79
PG 35:1; [M-H]-@6.13	ME222919	1.30	0.71	0.80	1.72
plasmenyl-PE 28:0; [M-H]-@5.79	ME222953	1.27	0.67	0.82	1.95
PE 35:4; [M-H]-@6.06	ME222895	0.83	0.63	1.41	1.44
PG 36:0; [M-H]-@6.93	ME222920	0.76	0.74	1.52	0.81
PE 35:0; [M-H]-@7.56	ME222892	0.89	1.36	0.66	1.61
CerP 35:1; [M-H]-@6.15	ME222835	1.22	1.05	0.72	1.06
plasmenyl-PE 33:0; [M-H]-@7.21	ME222956	1.42	0.82	0.77	0.90
FFA(18:1)	ME222840	1.34	0.92	0.75	0.92
FFA(18:2)	ME222841	1.34	0.95	0.73	0.89
PI 40:5; [M-H]-@6.01	ME222935	1.27	0.77	0.97	0.86
CerP 42:1; [M-H]-@8.17	ME222836	1.23	0.95	0.86	0.77
FFA(22:0)	ME222845	1.25	0.84	0.90	0.99
PE 35:3; [M-H]-@6.22	ME222894	1.19	0.90	0.91	0.97
Arachidonic acid	ME222815	1.18	0.97	0.86	0.95
PS 38:4; [M-H]-@6.01	ME222942	1.11	1.05	0.86	0.93
lysoPE 18:1; [M-H]-@1.75	ME222949	1.26	0.88	0.74	1.53
FFA(20:1)	ME222843	1.44	0.78	0.72	1.18
FFA(20:2)	ME222844	1.34	0.77	0.80	1.27
PA 37:2; [M-H]-@6.37	ME222857	0.93	1.03	1.11	0.69
PC 38:1; [M-Ac-H]-@7.71	ME222875	0.93	1.10	1.04	0.75
PA 35:1; [M-H]-@6.16	ME222854	0.89	0.95	1.22	0.70
PE 42:1; [M-H]-@8.83	ME222911	1.03	0.90	1.13	0.66
PE 32:0; [M-H]-@6.68	ME222886	0.89	0.97	1.14	1.01
CL 74:9; [M-2H](2-)@9.04	ME222829	0.89	1.08	1.06	0.89
PC 40:7; [M-Ac-H]-@6.08	ME222881	0.91	1.09	1.03	0.86
CL 72:9; [M-2H](2-)@8.79	ME222825	0.96	1.02	1.04	0.95
PI 38:4; [M-H]-@5.87	ME222932	0.97	0.97	1.07	0.95
CL 72:7; [M-2H](2-)@9.15	ME222823	0.96	0.99	1.04	1.01
FFA(16:0)	ME222838	1.00	1.01	0.99	1.00
FFA(18:0)	ME222839	0.99	1.01	1.00	0.99
FFA(20:0)	ME222842	1.02	1.05	0.94	0.95
CL 70:6; [M-2H](2-)@9.10	ME222819	0.95	1.08	0.98	1.01
FFA(24:0)	ME222849	0.94	1.08	1.00	0.96
lysoPE 22:6; [M-H]-@1.29	ME222952	0.79	1.25	0.96	1.10
PC 37:2; [M-Ac-H]-@7.10	ME222870	0.79	1.25	0.99	1.01
PC 42:9; [M-Ac-H]-@5.90	ME222883	0.80	1.17	1.06	0.95
PI 34:2; [M-H]-@5.30	ME222926	0.84	1.11	1.04	1.06
FFA(24:3)	ME222852	0.81	1.21	1.05	0.78
PS 34:2; [M-H]-@5.36	ME222937	0.70	1.22	1.12	0.91
CL 78:3; [M-2H](2-)@6.10	ME222831	0.76	1.12	1.06	1.31
lysoPE 22:5; [M-H]-@1.72	ME222951	0.71	1.15	1.07	1.37
PE 34:0; [M-H]-@6.53	ME222889	0.73	1.17	1.03	1.43
PS 36:3; [M-H]-@5.54	ME222940	0.89	1.20	0.87	1.29
PS 40:7; [M-H]-@5.45	ME222947	0.84	1.27	0.83	1.42
PE 40:8; [M-H]-@5.85	ME222910	1.01	0.87	1.03	1.37
plasmenyl-PE 32:0; [M-H]-@7.07	ME222955	0.95	0.87	1.06	1.43
plasmenyl-PE 38:6; [M-H]-@6.54	ME222965	0.95	0.88	1.04	1.52
PS 40:5; [M-H]-@6.12	ME222945	0.92	0.94	1.02	1.52
PC 37:3; [M-Ac-H]-@6.70	ME222871	1.02	0.93	0.93	1.51
PC 37:4; [M-Ac-H]-@6.49	ME222872	0.95	0.98	0.97	1.44
PE 36:2; [M-H]-@6.97	ME222896	0.93	0.99	0.97	1.49
PG 34:1; [M-H]-@5.84	ME222917	0.98	0.96	0.96	1.39
plasmenyl-PE 35:1; [M-H]-@7.45	ME222960	0.99	0.96	0.95	1.45
CL 76:7; [M-2H](2-)@6.70	ME222830	0.99	0.94	0.96	1.45
CerP 34:1; [M-H]-@5.84	ME222834	1.01	0.94	0.95	1.45
PE 38:6; [M-H]-@6.07	ME222905	1.00	0.93	0.95	1.45
PI 36:4; [M-H]-@5.26	ME222930	1.05	0.76	1.05	1.48
PA 36:2; [M-H]-@6.86	ME222855	1.09	0.86	0.93	1.48
plasmenyl-PE 40:6; [M-H]-@7.17	ME222967	1.14	0.79	0.93	1.52
PC 39:6; [M-Ac-H]-@6.36	ME222879	0.95	1.15	0.80	1.56
CL 74:7; [M-2H](2-)@6.10	ME222827	0.94	1.09	0.84	1.62
FFA(24:2)	ME222851	1.01	1.05	0.81	1.63
CL 72:5; [M-2H](2-)@9.51	ME222821	0.85	1.05	0.95	1.66
CL 74:1; [M-2H](2-)@6.67	ME222826	0.96	0.97	0.94	1.55
PC 32:2; [M-Ac-H]-@5.54	ME222864	0.94	1.00	0.92	1.60
PE 38:2; [M-H]-@6.83	ME222902	0.91	1.10	0.89	1.54
plasmenyl-PE 34:3; [M-H]-@6.31	ME222959	0.88	1.04	0.96	1.55
PE 35:1; [M-H]-@7.12	ME222893	1.09	0.94	0.86	1.47
PG 36:2; [M-H]-@6.13	ME222921	1.04	0.98	0.86	1.54
PE 40:3; [M-H]-@7.05	ME222908	1.10	0.89	0.85	1.66
PG 38:5; [M-H]-@5.50	ME222924	1.09	1.00	0.76	1.64
PC 33:3; [M-Ac-H]-@5.51	ME222865	1.00	1.11	0.84	1.30
PC 39:3; [M-Ac-H]-@7.33	ME222877	1.07	1.15	0.74	1.27
PC 44:4; [M-Ac-H]-@8.42	ME222884	1.12	1.05	0.77	1.28
FFA(22:2)	ME222847	1.18	0.94	0.78	1.39
PE 36:3; [M-H]-@6.52	ME222897	1.10	0.97	0.87	1.30
PC 31:0; [M-Ac-H]-@6.18	ME222862	1.00	0.92	1.04	1.18
PE 42:2; [M-H]-@8.55	ME222912	0.99	0.89	1.06	1.20
PE 42:4; [M-H]-@8.06	ME222913	0.93	0.87	1.14	1.21
PI 40:6; [M-H]-@5.84	ME222936	0.93	0.92	1.11	1.17
PE 38:1; [M-H]-@7.89	ME222901	0.80	1.03	1.14	1.19
PS 40:6; [M-H]-@5.88	ME222946	0.84	1.05	1.08	1.18
PI 34:1; [M-H]-@5.71	ME222925	0.87	1.01	1.08	1.16
PS 36:1; [M-H]-@6.43	ME222938	0.90	1.00	1.06	1.19
plasmenyl-PE 36:0; [M-H]-@8.10	ME222961	1.03	1.03	0.94	1.04
PI 40:4; [M-H]-@6.33	ME222934	1.01	0.99	0.99	1.06
PS 38:5; [M-H]-@5.57	ME222943	0.99	1.00	0.98	1.12
plasmenyl-PE 36:2; [M-H]-@7.29	ME222962	0.96	1.04	0.97	1.17
CL 72:8; [M-2H](2-)@8.94	ME222824	0.94	1.05	0.99	1.11
PI 38:3; [M-H]-@6.10	ME222931	0.93	1.04	1.00	1.13
PI 38:5; [M-H]-@5.43	ME222933	0.95	0.97	1.06	1.10
CL 72:6; [M-2H](2-)@9.35	ME222822	0.96	0.95	1.05	1.16
PI 36:3; [M-H]-@5.43	ME222929	0.93	1.00	1.03	1.15
PS 38:3; [M-H]-@6.22	ME222941	0.91	1.06	0.95	1.42
CL 82:13; [M-2H](2-)@6.29	ME222833	0.85	1.08	0.98	1.43
PE 40:7; [M-H]-@6.36	ME222909	0.86	1.10	0.96	1.43
PE 37:2; [M-H]-@7.16	ME222899	0.89	1.01	1.01	1.36
plasmenyl-PE 42:6; [M-H]-@7.73	ME222970	0.82	1.03	1.06	1.40
CL 78:5; [M-2H](2-)@6.38	ME222832	0.88	1.05	1.03	1.21
PI 36:2; [M-H]-@5.92	ME222928	0.93	1.02	1.01	1.21
plasmenyl-PE 36:3; [M-H]-@6.91	ME222963	0.91	1.05	0.99	1.24
PC 36:3; [M-Ac-H]-@6.32	ME222869	0.91	1.08	0.96	1.26
PE 38:5; [M-H]-@6.49	ME222904	0.91	1.10	0.95	1.23
PE 38:3; [M-H]-@7.22	ME222903	0.92	1.05	0.97	1.30
PG 34:2; [M-H]-@5.46	ME222918	0.89	1.07	0.98	1.30
FFA(22:1)	ME222846	1.02	1.00	0.92	1.29
PC 34:2; [M-Ac-H]-@6.19	ME222866	1.00	0.96	0.96	1.33
PS 36:2; [M-H]-@6.01	ME222939	0.97	1.01	0.94	1.34
plasmenyl-PE 34:0; [M-H]-@7.61	ME222957	0.95	1.00	0.97	1.33
plasmenyl-PE 34:2; [M-H]-@6.67	ME222958	0.96	0.99	0.98	1.30
PE 39:4; [M-H]-@7.12	ME222906	0.90	0.96	1.07	1.31
plasmenyl-PE 38:5; [M-H]-@6.75	ME222964	0.95	0.96	1.02	1.32
PC 19:2; [M-Ac-H]-@1.32	ME222859	0.97	0.94	1.02	1.28
plasmenyl-PE 40:5; [M-H]-@7.42	ME222966	0.96	0.97	1.01	1.27
PG 32:0; [M-H]-@5.80	ME222915	1.07	0.76	1.08	1.32
PE 40:2; [M-H]-@8.09	ME222907	1.07	0.85	1.04	1.13
PC 36:0; [M-Ac-H]-@7.72	ME222868	1.08	0.94	0.94	1.14
PA 34:2; [M-H]-@6.21	ME222853	1.05	0.96	0.93	1.23
PC 37:5; [M-Ac-H]-@5.98	ME222873	1.07	0.90	0.97	1.20
plasmenyl-PE 42:4; [M-H]-@8.03	ME222968	1.06	0.92	0.96	1.21
FFA(22:3)	ME222848	1.19	0.88	0.87	1.17
PA 36:3; [M-H]-@6.18	ME222856	1.14	0.86	0.92	1.31
PC 39:5; [M-Ac-H]-@6.51	ME222878	1.21	0.81	0.89	1.27

Factors:

F1	Subject group:HIGH-FA
F2	Subject group:LOW-FA
F3	Subject group:MID-FA
F4	Subject group:N/A

Data matrix